Lilly to Continue Investment in Alzheimer’s after Solanezumab Setback: Japan Development Chief

Toshio Fujimoto, Vice President, Medicines Development Unit Japan, Eli Lilly Japan Eli Lilly is poised to continue its development drive for Alzheimer’s disease (AD) drugs even after it dropped its once-hopeful monoclonal antibody solanezumab for the treatment of mild to...read more